The approval was based on evidence from the open-label phase 3 TATE trial in addition to well-controlled trials in adult and adolescent populations.
Asthma is one of the most common chronic childhood diseases and causes coughing, wheezing and difficulty breathing.
SEA is a serious form of asthma that occurs when white blood cells known as eosinophils become overreactive and cause inflammation in the lungs and airways.
